Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

Eli Lilly's obesity and Type 2 diabetes drug, Mounjaro, has gained approval from the Indian drug control authority for its KwikPen form.

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

Each Mounjaro KwikPen delivers four fixed doses of 0.6 mL and will available in the Indian market in six dose strengths of  2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Read on: ...

Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market with Novo Nordisk's Wegovy launch ...

India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant an ...

Mounjaro has released once-weekly injections that are helpful in managing type 2 diabetes along with showing remarkable results in sustainable weight loss. But how is this better than traditional ...

India’s drug regulator has given the nod to Eli Lilly’s once-a- week Mounjaro (tirzepatide) injection in the KwikPen format, giving a boost to the American pharma major’s expansion into the country ...

India approves Eli Lilly’s Mounjaro KwikPen, a once-weekly injection for type 2 diabetes and obesity, offering dual hormone action for improved blood sugar control and significant weight loss.

NEW DELHI: India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant announced on Thursday. The Central ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...